Regeneron Pharmaceuticals actions collapse at least four years after announcing a failed clinical trial

• Regeneron Pharmaceuticals (REGN) loses 18.89% today, reaching minimums not seen since May 6, 2021 in 485.00 $.
• The Aerify-2 study did not reach the criteria to demonstrate the efficacy of ITEPEKIBAM in patients with lung damage.

The titles of Regeneron Pharmaceuticals (REGN) marked a maximum of the day in $ 519.78, finding buyers who dragged the price of the share at minimum not seen since May 6, 2021 in 485.00 $. Currently, REGN operates at $ 490.09, falling 18.89% in the day.

Regeneron Pharmaceuticals disappoints investors after a disappointing clinical trial

The biotechnology company focused on the development and marketing of medicines, Regeneon Pharmaceuticals (REGN) has a drop of 18.89% on Friday after announcing the results for a treatment of chronic obstructive pulmonary disease (COPD).

The phase III Aerify-2 clinical trial sought to demonstrate the efficacy of ITEPEKIBAM. However, no significant benefit was demonstrated, since it only achieved a 2% reduction and did not reach the main valuation criteria.

After these results, the regn values ​​collapse to minimal not seen since May 6, 2021 in $ 485.00, quoting at the time of writing about $ 490.09.

Technical levels of regeneron pharmaceuticals

The regn values ​​reacted down from a short -term resistance given by the maximum of May 20 at $ 615.45. The next important resistance is observed at $ 748.25, maximum of March 10. Downwards, the key support is at $ 451.89 of March 3, 2021.

NDSN daily graphics